Septerna, Inc. SEPN
39.20 USD -0.25 (-0.63%)
Regular-session close
39.20 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
38.77 Day range 40.20
22.78 52-week range 53.34
- YTD
- +40.60%
- 1 year
- +69.70%
News
benzinga.com JP Morgan Maintains Overweight on Septerna, Raises Price Target to $51 JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the price target from $48 to $51.
seekingalpha.com Septerna, Inc. (SEPN) Presents at UBS Global Biopharma Conference 2026 Transcript Septerna, Inc. ( SEPN ) UBS Global Biopharma Conference 2026 November 16, 2026 9:00 AM EST Company Participants Jeffrey Finer - Co-Founder, CEO & Director Liz Bhatt - President & COO Conference Call…
fool.com Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE? Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.benzinga.com Stifel Maintains Buy on Septerna, Raises Price Target to $60 Stifel analyst Alex Thompson maintains Septerna (NASDAQ:SEPN) with a Buy and raises the price target from $49 to $60.
benzinga.com Septerna Q3 EPS $(0.57) Misses $(0.45) Estimate, Sales $18.881M Miss $20.780M Estimate Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.45) by 26.67 percent. This is a 416.67 percent decrease over earnings of $0.18…
benzinga.com Guggenheim Maintains Buy on Septerna, Raises Price Target to $65 Guggenheim analyst Seamus Fernandez maintains Septerna (NASDAQ:SEPN) with a Buy and raises the price target from $51 to $65.
benzinga.com Wells Fargo Maintains Overweight on Septerna, Raises Price Target to $61 Wells Fargo analyst Derek Archila maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the price target from $50 to $61.
benzinga.com Septerna Announces Selection Of SEP-204 As Potential Development Candidate For Treatment Of Graves’ Disease And TED; Reports Initial Preclinical Data Ahead Of Poster Presentation At 2026 ATA Annual Meeting Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpointsFavorable PK profile anticipated to support once-daily oral dosing in humansPhase 1…
